A5071133574- Biosimilars and Bioanalytical Methods
- Advanced Biosensing Techniques and Applications
- Mass Spectrometry Techniques and Applications
- Biosensors and Analytical Detection
- Protein purification and stability
- Metabolomics and Mass Spectrometry Studies
- Metabolism and Genetic Disorders
- Advanced Proteomics Techniques and Applications
- Amino Acid Enzymes and Metabolism
- Adipose Tissue and Metabolism
- Analytical Chemistry and Chromatography
- Innovative Microfluidic and Catalytic Techniques Innovation
- Fibroblast Growth Factor Research
- Hepatitis C virus research
- 3D Printing in Biomedical Research
- Kruppel-like factors research
- Cancer therapeutics and mechanisms
- Viral Infectious Diseases and Gene Expression in Insects
- HIV/AIDS drug development and treatment
- Cell Image Analysis Techniques
- Pancreatic and Hepatic Oncology Research
- Advanced biosensing and bioanalysis techniques
- Chemical Reactions and Isotopes
- Epigenetics and DNA Methylation
- Stress Responses and Cortisol
Crinetics Pharmaceuticals (United States)
2024-2025
Q2 Solutions (United States)
2016-2020
IQVIA (United States)
2012
Eli Lilly (United States)
2010
Background: Quantitation of biomarkers by LC–MS/MS is complicated the presence endogenous analytes. This challenge most commonly overcome calibration using an authentic standard spiked into a surrogate matrix devoid target analyte. A second approach involves use stable-isotope-labeled as analyte to allow in actual biological matrix. For both methods, parallelism between standards and must be demonstrated order ensure accurate quantitation. Results: In this communication, approaches are...
Immunoaffinity-mass spectrometry (IA-MS) is an emerging analytical genre with several advantages for profiling and determination of protein biomarkers. Because IA-MS combines affinity capture, analogous to ligand binding assays (LBAs), mass (MS) detection, this platform often described using the term hybrid methods. The purpose report provide overview principles demonstrate, through application, unique power potential technology. By combining target immunoaffinity enrichment use stable...
The 17
The 18th Workshop on Recent Issues in Bioanalysis (18th WRIB) took place San Antonio, TX, USA May 6-10, 2024. Over 1100 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest bioanalysis. WRIB included 3 Main Workshops 7 Specialized that together spanned 1 week allow an exhaustive thorough coverage all major issues bioanalysis biomarkers, immunogenicity, gene therapy, cell therapy vaccines....
The 2016 10th Workshop on Recent Issues in Bioanalysis (10th WRIB) took place Orlando, Florida with participation of close to 700 professionals from pharmaceutical/biopharmaceutical companies, biotechnology contract research organizations, and regulatory agencies worldwide. WRIB was once again a 5-day, weeklong event – A Full Immersion Week including Biomarkers Immunogenicity. As usual, it is specifically designed facilitate sharing, reviewing, discussing agreeing approaches address the most...
The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place Los Angeles/Universal City, California from 3 April to 7 with participation of close 750 professionals pharmaceutical/biopharmaceutical companies, biotechnology contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, weeklong event - A Full Immersion Week Bioanalysis, Biomarkers Immunogenicity. As usual, it specifically designed facilitate sharing, reviewing, discussing...
The 2018 12th Workshop on Recent Issues in Bioanalysis (12th WRIB) took place Philadelphia, PA, USA April 9-13, with an attendance of over 900 representatives from pharmaceutical/biopharmaceutical companies, biotechnology contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day full immersion bioanalysis, biomarkers immunogenicity. As usual, it specifically designed to facilitate sharing, reviewing, discussing agreeing approaches address the most current...
The 2019 13th Workshop on Recent Issues in Bioanalysis (WRIB) took place New Orleans, LA, USA April 1–5, with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, week-long event – full immersion week bioanalysis, biomarkers, immunogenicity gene therapy. As usual, it specifically designed to facilitate sharing, reviewing, discussing agreeing...
Recent advancements in immunocapture methods and mass spectrometer technology have enabled intact protein spectrometry to be applied for the characterization of antibodies other large biotherapeutics from in-life studies. Protein molecules not been traditionally studied by or screened catabolites same manner as small molecules, but landscape has changed. Researchers presented that can drug discovery development stages, others are exploring possibilities new approaches. However, a wide...
High-resolution MS (HRMS) has seen an uptake in use for discovery qual/quan workflows, however, its utilization late discovery/development been slow. Past reports comparing HRMS to triple quadrupole (QQQ) instrumentation date have indicated that instruments are capable of producing data acceptable regulated bioanalysis, however lack the sensitivity required sub ng/ml LLOQ assays. Recent advances closed gap with QQQ and even provided improved selectivity over SRM Herein, authors will describe...
In this study, we report a method for direct determination of gemcitabine incorporation into human DNA. Gemcitabine (dFdC), structural analog the nucleoside deoxycytidine (dC), derives its primary antitumor activity through interruption DNA synthesis. Unlike other surrogate measures, provides mechanistic end point useful dose optimization. samples (ca. 25 microg) were hydrolyzed using two-step enzymatic procedure to release dFdC which was subsequently quantified by LC-ESI-MS/MS stable...
Aim: Recombinant FGF21 analogs are under wide ranging investigations as a potential therapeutic agent for Type 2 diabetes, well other metabolic disorders. The endogenous is often used surrogate pharmacodynamic(PD) biomarker to assess drug efficacy and safety. Results & methodology: Immunocapture was performed using monoclonal antibody which had been generated bind specific domain of native the capture reagent. After immunocapture, enzymatic digestion FGF21-specific tryptic peptide monitored...
Adrenocorticotropic hormone 1–24 (ACTH[1–24]) has a similar effect as endogenous ACTH(1–39) to generate cortisol by targeting the MC2R receptor on adrenal gland. A new investigational ACTH antagonist drug is being developed treat diseases of excess (e.g., Cushing's disease) binding receptor. Administration ACTH(1–24) was used in Phase I clinical study assess ability this candidate suppress response stimulation. hybrid immunoaffinity-LCMS assay measuring with concentration range 10 400 pg/ml...
Aim: A novel LC–MS/MS method using a surrogate matrix and derivatization with fluorescamine was developed validated for simultaneous quantification of asymmetric dimethyl arginine symmetric arginine. Methods & results: Asymmetric arginine, corresponding internal standards were extracted protein precipitation followed by SPE. Derivatives analyzed turbo ion spray in the positive mode. Methodology successfully transferred across multiple preclinical species utilized support several...